🔎 Trials Near Me

Home › Heart Valve Diseases › NCT07213531

Enhanced Valves Interventions and Safe AI Generated End Results

RecruitingObservational study

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

Patients who have reached the age of legal majority under local laws.

* For TAVI group: All patients who have had TAVI with a third generation transcatheter heart valve (THV), with an available pre-procedural optimal quality CT scan as defined by an ECG- gating CT with:

  1. five to ten image volumes at cardiac phases from 5% to 95% R-R
  2. 0.625 mm slice thickness
  3. 0.625 mm spacing between slices
  4. 0.88 mm in-plane pixel spacing
* For TMVI group: Patients who have had a TMVI with a dedicated device and screen failures, with an available optimal quality CT scan.
* For TTVI group: Patients who have had a TTVI with a dedicated device and screen failures, with an available optimal quality CT scan.
* For M-TEER: All patient who have had a M-TEER with 1) G4 or newer iteration of MitraClip or 2) G2 or newer iteration of Pascal, with available pre-procedural TEE videos images from one of two vendors: Phillips or GE, with clear identifiable views of the Mitral valve, frame per second equal or higher than 40 frames per second, acceptable 3D reconstructions.
* For T-TEER: All patient who have had a T-TEER with G4 or newer iteration of TriClip or 2) G2 or newer iteration of Pascal, with available pre-procedural TEE videos images from one of two vendors: Phillips or GE, with clear identifiable views of the Tricuspid valve, frame per second equal or higher than 40 frames per second, acceptable transgastric image with acceptable 3D reconstructions.

Exclusion Criteria:

* For TAVI group: Valve-in-valve procedures
* For TMVI group: Valve-in-valve and valve-in-ring procedures
* For TTVI: Valve-in-valve and valve-in-ring procedures
* For M-TEER: G3 or older MitraClip, G1 Pascal
* For T-TEER: G3 Triclip, G1 Pascal

About the study

This non-interventional study aims to use artificial intelligence to improve the prediction of transcatheter heart valve interventions and optimize patient outcomes. It is based on the analysis of retrospective data from various specialized centers worldwide.

What is being tested

Sponsor: Montreal Heart Institute · Participants: 21,000 · Started: May 1, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT07213531

Locations in the U.S.

New YorkMontefiore Medical Center New York, New York

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.